基础胰岛素
医学
基础(医学)
内科学
2型糖尿病
糖尿病
内分泌学
胰岛素
作者
LIXIN GUO,Xiaolin Dong,Jianhua Ma,MING LIU,YIBING LU,Hongman Wang,Qingju Li,LING LI,YUYING DENG,JIAWEI XU
出处
期刊:Diabetes
[American Diabetes Association]
日期:2025-06-13
卷期号:74 (Supplement_1)
摘要
Introduction and Objective: Study SURPASS-CN-INS assessed efficacy and safety of tirzepatide (TZP) vs. placebo (PBO) in patients with T2D as an add-on to titrated insulin glargine alone or in combination with metformin with or without sodium-glucose transport protein 2 inhibitor. Methods: In this double-blind, PBO-controlled, 40-wk Phase 3 study, 257 patients with T2D (mean baseline [BL] age 56.7 y; T2D duration 12.1 y; HbA1c 8.71%; BMI 27.1 kg/m2) were randomized (1:1:1:1) to TZP (5 mg, 10 mg, 15 mg) or PBO. Primary efficacy measures included mean change in HbA1c from BL to 40 wk. Secondary measures included change in body weight (BW), fasting serum glucose (FSG) and proportion of patients achieving HbA1c targets. Results: All 3 TZP doses were superior to PBO in change from BL in HbA1c, BW, FSG and proportion of patients achieving all HbA1c targets at 40 wk (except for HbA1c target of <5.7% for TZP 5 mg, Table). TZP was generally well tolerated and the most common adverse events were gastrointestinal and generally mild to moderate in severity. Level 2 hypoglycemia incidence (<54 mg/dL) did not differ between TZP and PBO. No events of level 3 (severe) hypoglycemia were observed. Conclusion: TZP demonstrated superior and clinically meaningful improvements in glycemic control and BW loss without increasing hypoglycemia vs. PBO in Chinese patients with T2D when added to titrated basal insulin. Disclosure L. Guo: Research Support; Abbott, AstraZeneca, Bayer Pharmaceuticals, Inc, Eli Lilly and Company, Innovent Biologics, Merck & Co., Inc, MSD Life Science Foundation, Novo Nordisk A/S, Sanofi, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Tonghua Dongbao. X. Dong: None. J. Ma: None. M. Liu: None. Y. Lu: None. H. Wang: None. Q. Li: None. L. Li: None. Y. Deng: Employee; Lilly Diabetes. J. Xu: None. Funding Eli Lilly and Company
科研通智能强力驱动
Strongly Powered by AbleSci AI